NCT05293808

Platelet Aggregation in Diabetic Patients With Acute Coronary Syndrome Treated With Different Doses of Aspirin

Evaluation of Different Doses of Aspirin on Platelet Aggregation in Diabetic Patients With Acute Coronary Syndrome

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Federico II University · Academic / Other
• Sex: All
• Age: 40 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Diabetes is an important risk factor of coronary atherosclerosis, and it's well known that platelets of diabetic patients are hyper reactive and so resistant to common antithrombotic therapy. Moreover, in diabetic patients platelets are characterized by high turnover that is responsible of lack of protection by cardioaspirin at common dosage. The aim of our study is to asses the efficacy of different doses of aspirin in diabetic patients with acute coronary syndrome.

Conditions

• Acute Coronary Syndrome
• Diabetes Mellitus

Interventions

Type	Name	Description
DRUG	aspirin 100 mg bis in die	Patient will be randomized and after 10 days and 30 days we will measure platelets aggregation.
DRUG	aspririn 200 mg once daily	Patient will be randomized and after 10 days and 30 days we will measure platelets aggregation.
DRUG	aspirin 100 mg once daily	Patient will be randomized and after 10 days and 30 days we will measure platelets aggregation.

Timeline

• Start date: 2014-05-01
• Primary completion: 2014-10-01
• Completion: 2016-01-01
• First posted: 2022-03-24
• Last updated: 2024-02-23

Locations

1 site across 1 country: Italy